A Phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer

Investigational New Drugs

Volumn 22, Issue 1, 2004, Pages 69-73

  Miller, Kathy D ^a,d   Soule, Sharon E ^a   Haney, LaTrice G ^a   Guiney, Patricia ^a   Murry, Darryl J ^b   Lenaz, Luigi ^c   Sun, Show Li ^c   Sledge Jr , George W ^a  

^a INDIANA UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c Supergen   (United States)

^d Indiana Cancer Pavilion   (United States)

Author keywords

Chemotherapy; Clinical trial; Inhibitor; Topoisomerase

Indexed keywords

ANTINEOPLASTIC AGENT; RUBITECAN;

ABDOMINAL PAIN; ADULT; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG CLEARANCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; HUMAN; METASTASIS; NAUSEA; NEUTROPENIA; PAIN; PRIORITY JOURNAL; PRURITUS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT DISEASE; VOMITING;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BREAST NEOPLASMS; CAMPTOTHECIN; FEMALE; HUMANS; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 1042291302     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000006176.84915.71     Document Type: Article

References (14)

1. Landis SH, Murray T, Bolden S et al.: Cancer statistics, 1998. CA Cancer J Clin 48(1): 6-29, 1998
2. Harris J, Lippman ME, Morrow M, Osborne CK (ed.): Diseases of the Breast. Lippincott Williams & Wilkins, Philadelphia, 2000, 755
3. Blum J, Jones SE, Buzdar A, LoRusso P, Kuter I, Vogel C, Osterwalder B, Burger H, Brown CS, Griffin T: a multicenter Phase II trail of Xeloda (capecitabine) in paclitaxel refractory metastatic breast cancer. J Clin Oncol 17(2): 485-493, 1999
4. McLeod H, et al.: Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer 59: 607-611, 1994
5. Gerritts CJ, DeJong MJ, Schellens JH, Stoter G, Verweij J: Topoisomerase I inhibitors: The relevance of prolonged exposure for present clinical development. Br J Cancer 25: 49-58, 1983
6. Gottlieb JA, Guarino AM, Call JB: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 56: 103-105, 1972
7. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG: Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95-101, 1972
8. Amorino GP, Hercules SK, Mohr PJ, Rothenberg ML, Choy H: Enhancement of radiation effects in vitro by the orally active camptothecin analog, RFS2000 (9-nitro-20(S)-camptothecin). Proc Am Soc Clin Oncol 18: 449, 1999 (Abstract 1733)
9. Pantazis P, Kozielski AJ, Vardeman DM et al.: Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncology Res 5: 273-281, 1993
10. Moulton S, Pantazis P, Epstein JS, Sadaie: 9-Nitroamino-camptothecin inhibits tumor-necrosis factor-mediated activation of the human immunodeficiency virus type 1 (HIV-1) and enhances apoptosis in a latently infected T-cell clone. AIDS Res Human Retroviruses 14: 39-49, 1998
11. Verschraegen CF, Natelson EA, Giovanella BC: A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anti-Cancer Drugs 9: 36-44, 1998
12. Natelson EA, Giovanella BC, Verschraegen CF, Fehir KM, Delpolyi PD, Harris N, and Stehlin JS: Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann New York Acad Sci 803: 224-230, 1996
13. Ikeda H, Koshiba R: A pilot study of irinotecan hydrochloride for metastatic breast cancer - efficacy as a salvage therapy. Jpn J Cancer Chemother 27(5): 723-727, 2000
14. Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR: Randomized phase II study of 2 schedules of irinotecan (PT-11) for patients with refractory metastatic breast cancer (MBC): An NCCTG Cooperative Group study. Proc ASCO 21:52a, 2002 (Abstract #206)